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Introduction
Chronic obstructive pulmonary disease (emphysema) 
is the leading diagnosis for recipients requiring lung 
transplantation (LT) (1). Together with alpha 1-antitrypsin 
deficiency (A1ATD), the rate is about one third of all 
lung transplantations done (1). In spite of the 63.530 lung 
transplantations performed, the question regarding the 
appropriate timing of the procedure in emphysema (EMP) 
recipients and the type of procedure is still challenging 
(1,2). This review article includes patient selection, bridging 
strategies until lung transplantation, surgical approach, 
and choice of the procedure, and functional outcome in 
emphysema recipients.
Recipient selection
Lung transplantation (LT) is proved to be effective in 
patients with end-stage lung disease who are failing optimal 
therapy (3). Recipient selection and the timing of LT is 
an important (4). Most of the transplant centers use the 
guidelines published by the International Society for Heart 
and Lung Transplantation (ISHLT), however it may also 
be done on individual bases (3-5). Because of the natural 
history of most recipients with EMP, it could be difficult 
to decide which patient should be listed for LT (4). LT is 
a complex surgery and like other major surgeries, it might 
lead to complications and mortality. For this reason, it is 
extremely important to choose a recipient in whom expected 
survival is at less equal or comparable to the survival 
without surgery (4). Forced expiratory volume in 1 second 
(FEV1) is used as a prognostic indicator for survival of EMP 
recipients (4). Studies from Vestbo et al. and Nishimura 
et al. have shown that drop in lung function up to 5-year 
period was minimal (6,7). Also, in A1ATD recipients, 
Seersholm et al. reported 50% 2-year survival when FEV1 
is 15% (8). On the other hand, degree of airway obstruction 
is not the only factor that affects the natural history EMP. 
Age, hypoxemia, hypercapnia, pulmonary hypertension, 
low body mass index, poor exercise capacity, magnitude of 
dyspnea, and emphysema severity are reported to be also 
important risk factors (2,4,6,9,10). 
Unfortunately, these factors have limited strength to 
define the prognosis of a patient. In order to overcome this 
limitation, Celli et al. have put together those confounders 
in order to predict outcome in EMP patients (11). They 
included four factors that might predict an increased risk 
of death in EMP patients. They named it as BODE index. 
The factors they used are body mass index (B), airflow 
Review Article on Lung Emphysema
Inci. Lung transplantation for emphysema
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(21):1473 | http://dx.doi.org/10.21037/atm-20-805
Page 2 of 8
obstruction measured by FEV1 (O), dyspnea score (D), 
and exercise capacity measured by 6-minute walking test 
(E) (11). This scoring system (BODE Index) ranges from 
0 to 10, with a higher score indicating higher risk of death 
(2,11). Increase in BODE index greater than 1 point 
over a 6- to 24-month period reported to double the risk 
of death (12). The recent ISHLT guidelines published 
in 2015 includes BODE index in listing patients for 
EMP (3). BODE index of more than five is recommended 
for referral (3,11). ISHLT guidelines recommend listing 
with a BODE score of 7 to 10 or at least one of the 
following: (I) history of hospitalization for exacerbation 
associated with acute hypercapnia (pCO2 >50 mmHg); 
(II) pulmonary hypertension and/or cor pulmonale, 
despite oxygen therapy; or (III) FEV1 <20% and either 
diffusing capacity for carbon monoxide (DLCO) <20% or 
homogeneous distribution of emphysema (3). 
Early referral for patients who do not meet above 
mentioned criteria is also recommended as this might allow 
the transplant team to identify and address factors that 
might compromise the future candidacy of the patient, such 
as ongoing smoking, extremes of weight, poor functional 
status, severe osteoporosis, excessive corticosteroid use, and 
coronary artery disease (2).
Lung transplantation is a complex treatment option 
with a significant risk of perioperative morbidity and 
mortality. ISHLT guidelines for absolute contraindications 
are as follows (3): malignancy in the last 2 years, with the 
exception of cutaneous squamous and basal cell tumors; 
untreatable advanced dysfunction of another major organ 
system (e.g., heart, liver, or kidney); non-curable chronic 
extra-pulmonary infection including chronic active viral 
hepatitis B, hepatitis C, and human immunodeficiency 
virus; significant chest wall/spinal deformity; documented 
nonadherence or inability to follow through with medical 
therapy or office follow-up, or both; untreatable psychiatric 
or psychological condition associated with the inability 
to cooperate or comply with medical therapy; absence of 
a consistent or reliable social support system; substance 
addiction (e.g., alcohol, tobacco, or narcotics) that is either 
active or within the last 6 months.
The widely accepted relative contraindications reported 
by ISHLT are (3): age older than 65 years, critical or 
unstable clinical condition, severely limited functional status 
with poor rehabilitation potential, colonization with highly 
resistant or highly virulent bacteria, fungi, or mycobacteria, 
severe obesity defined as a body mass index (BMI) exceeding 
30 kg/m2 (13), severe or symptomatic osteoporosis. 
Extracorporeal membrane oxygenation (ECMO) 
as a bridge to LT
In EMP patients hypercapnia or hypoxemia will develop 
despite maximal support and therefore ECMO would 
be their only chance to survive until a donor lung could 
be found (14). With the improved knowledge, bridging 
patients on ECMO is not a contraindication to LT 
with comparable one-and 2-year survivals to those that 
underwent LT without preoperative ECMO use (15-18).
Lung volume reduction surgery
Compared to medical management strategies lung volume 
reduction surgery (LVRS) and LT have been shown to provide 
superior survival in selected patients with EMP (19,20).
Although the experience with LVRS has grown over the 
last years, the selection of patients for LVRS is still a matter 
of controversy when the emphysema distribution is not 
heterogeneous and differs widely among centers (21-25). 
This concept was first reported by Brantigan (26) and re-
introduced by Cooper et al. (27). 
For young patients LVRS does not replace the need for 
LT. However, LVRS is an option for definitive treatment for 
older patients with significant comorbidities, in whom the 
transplantation is not indicated.
LT improves the quality of life, however the procedure 
itself is complex, and requires life-long immunosuppression 
and confronted to side-effects of these drugs (28).
However, donor shortage is still the main limitation for 
LT and LVRS is rarely performed (28). In addition, LVRS 
might be a bridging strategy to LT due to the limited organ 
pool (29). LVRS is indicated in less advanced lung disease 
compared to LT candidates. However, there is a group 
of patients in which both procedures can be offered with 
improved outcomes (30). Our selection criteria in Zurich 
for LVRS and/or LT is summarized in Figure 1. 
In heterogeneous and in homogenous emphysema 
relevant symptomatic and functional improvements has 
been reported. Three to 6 months after operation maximal 
values were observed with a subsequent decline towards 
preoperative levels over the following years (31,32). LVRS 
can be performed in selected patients with advanced EMP 
who has severe hyperinflation, if the FEV1 and the carbon 
monoxide diffusing capacity are not below 20% (30-32).
Discussion continues about the effect of pre-transplant 
LVRS on outcomes after lung transplantation. Early 
reports demonstrated comparable outcomes (33-35). 
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The main limitation of these studies were the lack of 
patient selection criteria. Backhus et al. from University 
of Washington, Seattle reported inferior results in 
recipients undergoing LT following LVRS compared to 
LT alone (36). In this paper 174 patients underwent LT 
for EMP in 15 years of a period. Among these, 36 had 
pre-transplantation LVRS. They reported that selecting 
patients for LT with a history of LVRS requires a careful 
assessment as those recipients experienced inferior survival 
after lung transplantation (36). 
We recently published our single center experience for 
patients undergoing LVRS followed by LT (n=52) (37). This 
patient population was, to our knowledge, the largest cohort 
published so far. We found that outcomes were not different 
for recipients who underwent combined procedures 
when compared to recipients who underwent LT only. In 
addition, Seattle Group reported longer operation times 
and hospital stays during LT in patients with a history of 
LVRS (36). 
In EMP patients who are potential candidates for LT, 
LVRS might improve lung function, symptoms and quality 
of life that might postpone LT for couple of years (30,37). 
Although there are still concerns (36), previous LVRS had 
no negative effect on outcome following LT and these 
patients do not lose their chance for LT (30,37).
Surgical approach
Both bilateral lung transplantation (BLT) and single lung 
transplantation (SLT) can be performed in EMP recipients. 
Rarely, if severe cardiac pathology presents, heart-lung 
transplantation can be performed. These patients with 
secondary pulmonary hypertension can even undergo SLT 
without any graft dysfunction and with improved pulmonary 
hemodynamics in the early perioperative period (38,39). 
SLT can be performed via antero-lateral or postero-
lateral thoracotomy incision. BLT was initially performed via 
clamshell incision (bilateral trans-sternal thoracotomy) (4). 
Clamshell incision is later replaced by the most centers 
with bilateral antero-lateral thoracotomy incision without 
transverse sternotomy (40-42).
Choice of the procedure
Recent international registry (ISHLT) reported 7.8 years of 
median survival in recipients that received BLT compared 
to 4.8 years in SLT recipients (Figure 2) (1). These rates 
increase to 10.2 years in BLT recipients and 6.5 years in 
SLT recipients who survive the first year following LT (1). 
According to the recent ISHLT registry 22.121 lung 
transplants were performed for EMP (N=19,152) and 
A1ATD (N=2,969) from January 1995 to June 2018 (1). 
LVRS








• All morphologies in 
the absence of DLCO 
<20% and/or PAH
• No significant 
bronchiectasis
LVRS-LT







• Age <65 years 
• FEV1 <15-20%
• DLCO <20%
• Moderate to 
severe PAH






• Steroid intake 
>20mg/d
Patient selection criteria for LVRS and/or LT
Figure 1 Patient selection criteria in Zurich for LVRS and/or LT based on patients’ age, pulmonary function tests, radiologic findings, 
pulmonary hypertension, and steroid intake. LVRS, lung volume reduction surgery; LT, lung transplantation; PAH, pulmonary hypertension; 
CT, computed tomography.
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In 2005, only approximately 50% of the transplantations 
performed for EMP were BLT. Thereafter the rate of BLT 
increased up to 81% in 2017 (1). Ventilation-perfusion 
mismatching following single lung transplantation and 
possible graft dysfunction have influenced the centers not 
to perform SLT. Stevens et al. demonstrated ventilation and 
perfusion mismatch in SLT recipients (43). In spite of this 
report, transplant centers started to perform SLT in the 
early 90’s with good results (44,45). 
Majority of the centers prefer BLT, due to complications 
that might occur from the native lung (45-48). Short total 
ischemic time and operation time are advantageous of SLT 
that lead to lower morbidity and mortality (49). 
Sunderasan et al. demonstrated the outcomes of their 
EMP patients who underwent LT (50). They reported 
comparable outcome in patients received BLT or SLT. 
5-year survival was 53% in BLT recipients and 41% in SLT 
recipients (50). In another study, Cassivi et al. reported 
5-year survival rate of 66.7% in BLT and 44.9% in SLT 
recipients (51) Delgado et al. from Spain demonstrated 
similar cumulative 5-year survival rate, excluding 
preoperative mortality, with 54% overall, 59% for SLT and 
56% for BLT. The frequency of BOS was 34% in SLT and 
42% in BLT. Acute rejection episodes and perioperative 
complication rates were also comparable between SLT and 
BLT groups (52). 
Survival after both SLT and BLT in EMP patients 
was analyzed (53). Among included 9883 patients with 
EMP, 36% underwent BLT, and 64% SLT. The median 
survival after either type of LT for patients with EMP was 
5.0 years (95% CI: 4.8–5.2). The proportion of patients who 
had BLT increased from 21.6% in 1993 to 56.2% in 2006. 
Median survival time after BLT was longer than that after 
SLT: 6.4 years (6.02–6.88) versus 4.6 years (P<0.0001). This 
study showed that BLT did not have survival advantage in 
patients over 60 years of age at transplantation. The authors 
stated that BLT gives longer survival compared to SLT and 
in recipients who are younger than 60 years of age (53).
Meyer et al. studied 2,260 lung transplant recipients 
who underwent lung transplantation for EMP (54). 
30-day, 1 year, and 5 years survival (%) in patients aged 
<50 years were 93.6, 80.2, and 43.6, respectively, for the 
SLT patients, and 94.9, 84.7, and 68.2, respectively in BLT 
cases. For patients aged 50 to 60 years, survival rates (%) 
were 93.5, 79.4, and 39.8 for the SLT patients compared 
with 93.0, 79.7, and 60.5 for the BLT patients. Recipients 
aged >60 years, survival (%) was 93.0, 72.9, and 36.4 in SLT, 
compared to 77.8 and 66.0 in BLT. The multivariate model 
showed a higher risk ratio for mortality in patients aged 40 
to 57 years who received SLT versus BLT. They stated that 
SLT might offer acceptable early survival for patients with 
end-stage respiratory failure. However, long-term survival 
data favors BLT in recipients younger than 60 years-old. 
Their data suggest that BLT approach offers a significant 
survival advantage to recipients younger than 60 years of 
age (54). In our recent publication, we demonstrated that 
5-year survival rate for those <60 years old was significantly 
better than those of ≥60 years (84% and 54%, P=0.05) (47).
A multicenter study showed that BLT was superior to 
SLT (55). Based on these studies, BLT has similar short-
term results compared with SLT, but better long-term 
results (56). 
There are also other reasons why the transplant 
community prefer to perform BLT instead of SLT in EMP 
recipients (56). Hyperinflation of the native lung, which was 
reported to be between 5% to 15% of cases, is one of the 
reasons (45,57-59). Native lung pneumonia (10% to 20%) 
may lead to 20% of mortality rate (60,61). In 3% of the 
recipients lung cancer can occur in the native lung (62,63). 
Functional outcomes
Following LT physiologic parameters like FEV1 and FVC 
improve in EMP recipients (64). Cases who undergo BLT 




















Kaplan-Meier Survival by Procedure Type
(Transplants: January 1992—June 2017)
Diagnosis: COPD
Figure 2 Survival curve in COPD recipients who received bilateral 
or single lung transplantation from recent international registry 
(ISHLT) reported 7.8 years of median survival in recipients that 
received bilateral compared to 4.8 years in single lung transplant 
recipients. Kaplan-Meier method was used to calculate survival. 
Survival rates were compared using the log-rank test statistic.
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to 60%, whereas the FEV1 exceeds 80% in BLT (50,65,66).
6MWT distance did not show significant difference in 
daily physical activity between the SLT and BLT among 
recipients (67,68).
In addition, exercise performance as assessed by the age-
adjusted parameter of maximum oxygen consumption was 
also comparable between SLT and BLT (69,70).
The type of the procedure and development of 
bronchiolitis obliterans syndrome (BOS) attracted the 
attention of several investigators. These studies failed to 
detect a difference in incidence of bronchiolitis obliterans 
syndrome (BOS) among recipients of SLT versus BLT 
(44,50,66). On the other hand, increased freedom from 
BOS in BLT recipients was reported at both 3 and 5 years 
following LT (71). 
Conclusion
Careful patient selection and to offer the best surgical 
option are extremely important to reach successful outcomes 
in emphysema patients. Lung transplantation is an option 
for those who have failed optimal medical treatment. LVRS 
postpones the need for LT for up to several years and leads 
to improvement in nutritional and functional status until 
LT. LVRS does not compromise the outcome in case of 
future LT. Bilateral LT offers the best long-term outcome 
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